帕金森病(PD)是一种由多巴胺能神经元死亡引起的退行性神经疾病,which,反过来,导致运动和认知功能受损。早期诊断对PD的良好预后具有重要意义。目前,诊断PD的唯一方法是通过病史,目前的症状,和神经系统检查。这个,然而,只有在患者的PD进展足够后才能发生。脑脊液(CSF)和血浆中的生物标志物,然而,可以深入了解PD和可能并发的痴呆的早期进展,这也可以帮助开发新的治疗方法。具体来说,本系统综述探讨了α-突触核蛋白(α-syn)和微管蛋白相关单位(Tau)蛋白,并分析了它们作为生物标志物的潜在作用,同时还探讨了尼洛替尼和免疫疗法作为潜在的治疗选择.PubMed,PubMedCentral(PMC),Medline,和Cochrane图书馆作为相关文献的数据库,资格标准和质量检查-多重系统审查评估(AMSTAR)工具,纽卡斯尔-渥太华质量评估量表,Cochrane偏差风险评估2(RoB2),和叙事评价量表(SANRA)-被应用。其余文献研究了PD和帕金森病痴呆(PDD)的各个方面以及相关的生物标志物。从10项研究中,2,361名参与者,PD患者和健康对照(HCs),进行了评估和比较。各种评估量表,如统一帕金森病评定量表第三部分(UPDRSIII),用于确定患者PD的严重程度或进展,同时还寻求与α-syn和总Tau(t-Tau)的显着相关性。缺乏标准化的临床试验导致报告相互矛盾。因此,虽然文章普遍认为α-syn和Tau蛋白分析在诊断中的潜在功效,预后,以及PD和PDD的治疗,他们还主张进一步的测试和试验。
Parkinson\'s disease (PD) is a degenerative neurological disorder resulting from the death of dopaminergic neurons, which, in turn, results in impaired motor and cognitive functions. Early diagnosis is important in achieving a good prognosis for PD. Currently, the only approved way to diagnose PD is through medical history, current symptoms, and neurological examination. This, however, can only happen after PD progresses far enough in patients. Biomarkers in cerebrospinal fluid (CSF) and blood plasma, however, may provide insight into the early progress of PD and potentially concurrent dementia, which can also aid in the development of novel treatments. Specifically, this systematic review explores alpha-synuclein (α-syn) and tubulin-associated unit (Tau) proteins and analyzes their potential roles as biomarkers while also touching on nilotinib and immunotherapy as potential treatment options. PubMed, PubMed Central (PMC), Medline, and Cochrane Library serve as the databases for relevant literature, upon which eligibility criteria and quality checks - Assessment of Multiple Systematic Review (AMSTAR) tool, Newcastle-Ottawa Quality Assessment Scale, Cochrane risk-of-bias assessment 2 (RoB2), and Scale for the Assessment of Narrative Review (SANRA) - were applied. The remaining literature examines the various aspects of PD and Parkinson\'s disease dementia (PDD) and associated biomarkers. From 10 studies, 2,361 participants, both PD patients and healthy controls (HCs), were assessed and compared. Various assessment scales, such as the Unified Parkinson\'s Disease Rating Scale part III (UPDRS III), were used to ascertain the severity or progression of PD in patients while also seeking a noticeable correlation with α-syn and total Tau (t-Tau). The lack of standardized clinical testing has led to conflicting reports. Thus, while the articles generally agree on the potential efficacy of α-syn and Tau protein analysis in the diagnosis, prognosis, and treatment of PD and PDD, they also argue for further testing and trials.